{"success":true,"data":{"pressRelease":{"id":"9433","rtpr_id":"nPn2G5VqGa","ticker":"AQST","exchange":"NASDAQ","all_tickers":["AQST"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"PR Newswire","published_at":"2026-04-27T16:00:00.437Z","article_body":"Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm\n\nPR Newswire\n\nNEW YORK, April 27, 2026\n\nNEW YORK, April 27, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman,\nLLC, a nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ:\nAQST) and certain of its officers.\n\n(https://mma.prnewswire.com/media/439152/Bronstein_Gewirtz_and_Grossman_LLC_logo.html)\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aquestive Therapeutics\nsecurities between June 16, 2025 and January 8, 2026, both dates inclusive\n(the \"Class Period\"). Such investors are encouraged to join this case by\nvisiting the firm's site: bgandg.com/AQST.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=3569675851&u=https%3A%2F%2Fbgandg.com%2FAQST%2F%3Futm_source%3Dprnewswire%26utm_medium%3Dpressrelease%26utm_campaign%3DAQST&a=bgandg.com%2FAQST.)\n\nAquestive Therapeutics Case Details\n\nThe Complaint alleges that, throughout the relevant period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n\n 1. the timeline for approval and launch of Aquestive's New Drug Application\n(\"NDA\") for Anaphylm (dibutepinephrine) sublingual film was materially\noverstated;\n 2. Defendants' statements expressing confidence in the NDA submission and their\nrepeated assertions that Anaphylm would receive approval by the Prescription\nDrug User Fee Act (\"PDUFA\") date of January 31, 2026 lacked a reasonable\nbasis;\n 3. the NDA faced significant risks related to human factors associated with the\nuse of the sublingual film, including packaging, administration, use, and\nlabeling; and\n 4. Defendants concealed or minimized the material impact of these human‑factors\nissues on the likelihood and timing of regulatory approval.\nWhat's Next for Aquestive Therapeutics Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/AQST.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=3569675851&u=https%3A%2F%2Fbgandg.com%2FAQST%2F%3Futm_source%3Dprnewswire%26utm_medium%3Dpressrelease%26utm_campaign%3DAQST&a=bgandg.com%2FAQST.)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911\n(tel:+9175900911) . If you suffered a loss in Aquestive Therapeutics you have\nuntil May 4, 2026, to request that the Court appoint you as lead plaintiff.\nYour ability to share in any recovery doesn't require that you serve as lead\nplaintiff.\n\nNo Cost to Aquestive Therapeutics Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class\nactions on a contingency fee basis. That means we will ask the court to\nreimburse us for out-of-pocket expenses and attorneys' fees, usually a\npercentage of the total recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aquestive Therapeutics\nSecurities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=3379821250&u=https%3A%2F%2Fwww.bgandg.com%2F&a=www.bgandg.com)\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=252451777&u=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fperetz-bronstein-65a1b411&a=Peretz+Bronstein)\n, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=1183456647&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbronstein-gewirtz-%26-grossman-llc%2F&a=LinkedIn)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=2820110889&u=https%3A%2F%2Fx.com%2Fbgandg_law&a=X)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=216929939&u=https%3A%2F%2Fwww.facebook.com%2FBGandG%2F&a=Facebook)\n, or Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=2541771898&u=https%3A%2F%2Fwww.instagram.com%2Fbg_and_g%2F&a=Instagram)\n.\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\n\nBronstein, Gewirtz & Grossman, LLC\n\n917-590-0911 (tel:+9175900911) | info@bgandg.com (mailto:info@bgandg.com)\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bronstein-gewirtz--grossman-llc-urges-aquestive-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm-302750140.html\n(https://www.prnewswire.com/news-releases/bronstein-gewirtz--grossman-llc-urges-aquestive-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm-302750140.html)\n\nSOURCE Bronstein, Gewirtz & Grossman, LLC\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/439152/Bronstein_Gewirtz_and_Grossman_LLC_logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2G5VqGa","title":"Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"PR Newswire","ticker":"AQST","created":"2026-04-27T16:00:00.437Z","tickers":["AQST"],"exchange":"NASDAQ","article_body":"Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm\n\nPR Newswire\n\nNEW YORK, April 27, 2026\n\nNEW YORK, April 27, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman,\nLLC, a nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ:\nAQST) and certain of its officers.\n\n(https://mma.prnewswire.com/media/439152/Bronstein_Gewirtz_and_Grossman_LLC_logo.html)\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aquestive Therapeutics\nsecurities between June 16, 2025 and January 8, 2026, both dates inclusive\n(the \"Class Period\"). Such investors are encouraged to join this case by\nvisiting the firm's site: bgandg.com/AQST.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=3569675851&u=https%3A%2F%2Fbgandg.com%2FAQST%2F%3Futm_source%3Dprnewswire%26utm_medium%3Dpressrelease%26utm_campaign%3DAQST&a=bgandg.com%2FAQST.)\n\nAquestive Therapeutics Case Details\n\nThe Complaint alleges that, throughout the relevant period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n\n 1. the timeline for approval and launch of Aquestive's New Drug Application\n(\"NDA\") for Anaphylm (dibutepinephrine) sublingual film was materially\noverstated;\n 2. Defendants' statements expressing confidence in the NDA submission and their\nrepeated assertions that Anaphylm would receive approval by the Prescription\nDrug User Fee Act (\"PDUFA\") date of January 31, 2026 lacked a reasonable\nbasis;\n 3. the NDA faced significant risks related to human factors associated with the\nuse of the sublingual film, including packaging, administration, use, and\nlabeling; and\n 4. Defendants concealed or minimized the material impact of these human‑factors\nissues on the likelihood and timing of regulatory approval.\nWhat's Next for Aquestive Therapeutics Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/AQST.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=3569675851&u=https%3A%2F%2Fbgandg.com%2FAQST%2F%3Futm_source%3Dprnewswire%26utm_medium%3Dpressrelease%26utm_campaign%3DAQST&a=bgandg.com%2FAQST.)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911\n(tel:+9175900911) . If you suffered a loss in Aquestive Therapeutics you have\nuntil May 4, 2026, to request that the Court appoint you as lead plaintiff.\nYour ability to share in any recovery doesn't require that you serve as lead\nplaintiff.\n\nNo Cost to Aquestive Therapeutics Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class\nactions on a contingency fee basis. That means we will ask the court to\nreimburse us for out-of-pocket expenses and attorneys' fees, usually a\npercentage of the total recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aquestive Therapeutics\nSecurities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=3379821250&u=https%3A%2F%2Fwww.bgandg.com%2F&a=www.bgandg.com)\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=252451777&u=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fperetz-bronstein-65a1b411&a=Peretz+Bronstein)\n, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=1183456647&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbronstein-gewirtz-%26-grossman-llc%2F&a=LinkedIn)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=2820110889&u=https%3A%2F%2Fx.com%2Fbgandg_law&a=X)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=216929939&u=https%3A%2F%2Fwww.facebook.com%2FBGandG%2F&a=Facebook)\n, or Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4670263-1&h=2541771898&u=https%3A%2F%2Fwww.instagram.com%2Fbg_and_g%2F&a=Instagram)\n.\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\n\nBronstein, Gewirtz & Grossman, LLC\n\n917-590-0911 (tel:+9175900911) | info@bgandg.com (mailto:info@bgandg.com)\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bronstein-gewirtz--grossman-llc-urges-aquestive-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm-302750140.html\n(https://www.prnewswire.com/news-releases/bronstein-gewirtz--grossman-llc-urges-aquestive-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm-302750140.html)\n\nSOURCE Bronstein, Gewirtz & Grossman, LLC\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/439152/Bronstein_Gewirtz_and_Grossman_LLC_logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-27T16:00:00.482310289Z","server_sent_at_ms":1777305600482},"received_at":"2026-04-27T16:00:00.541Z","source_url":null},"analysis":{"id":"7136","press_release_id":"9433","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["class action lawsuit alleging securities fraud","allegations that lead asset approval timeline was overstated","allegations of concealed human factors risks regarding Anaphylm"],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman LLC announced that a class action lawsuit has been filed against Aquestive Therapeutics alleging violations of federal securities laws.\n\nThe complaint claims the company made materially false and misleading statements regarding the approval and launch timeline for its lead asset, Anaphylm (dibutepinephrine).\n\nSpecifically, the lawsuit alleges that defendants lacked a reasonable basis for confidence in meeting the PDUFA date and concealed material risks related to human factors in the sublingual film's design.\n\nInvestors who purchased AQST securities between June 16, 2025, and January 8, 2026, have until May 4, 2026, to request appointment as lead plaintiff.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Securities fraud suit targets AQST over alleged misrepresentations of Anaphylm approval timeline."},"keyFigures":{"customDimensions":{"pdufa_date":"January 31, 2026","class_period_end":"January 8, 2026","class_period_start":"June 16, 2025","lead_plaintiff_deadline":"May 4, 2026"}},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner of Bronstein, Gewirtz & Grossman, LLC"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["Anaphylm","dibutepinephrine"],"companies":[{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"defendant"},{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"A class action lawsuit alleging securities fraud regarding the company's lead asset creates significant legal uncertainty and potential reputational damage, though the outcome is uncertain."},"tickerRelevance":{"others":[],"primary":"AQST"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"legal_filing","sectorWeight":"biotech"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Bronstein, Gewirtz & Grossman LLC announced that a class action lawsuit has been filed against Aquestive Therapeutics alleging violations of federal securities laws.\n\nThe complaint claims the company made materially false and misleading statements regarding the approval and launch timeline for its lead asset, Anaphylm (dibutepinephrine).\n\nSpecifically, the lawsuit alleges that defendants lacked a reasonable basis for confidence in meeting the PDUFA date and concealed material risks related to human factors in the sublingual film's design.\n\nInvestors who purchased AQST securities between June 16, 2025, and January 8, 2026, have until May 4, 2026, to request appointment as lead plaintiff.","key_figures":{"customDimensions":{"pdufa_date":"January 31, 2026","class_period_end":"January 8, 2026","class_period_start":"June 16, 2025","lead_plaintiff_deadline":"May 4, 2026"}},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner of Bronstein, Gewirtz & Grossman, LLC"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["Anaphylm","dibutepinephrine"],"companies":[{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"defendant"},{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff counsel"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-27T18:49:07.041Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"legal_filing","sectorWeight":"biotech"}},"durationMs":64347,"modelName":"glm-4.7"}}